3 #AHA24 ScientificSessions.org Today at Sessions Late-Breaking Science LBS.01: Celebrating a Century of Cardiovascular Science: From Prevention to Treatment, to Cure 8:30-9:45 a.m. | Main Event I • Effects of Intensive Blood Pressure Control in Patients With Type 2 Diabetes (BPROAD) • Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial • Nexiguran Ziclumeran (nex-z, also known as NTLA-2001), an Investigational in Vivo CRISPRBased Therapy for Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Interim Report of the Phase 1 Study LBS.02: Redefining Arrhythmia Treatment: Pushing Boundaries 1:30-2:45 p.m. | Main Event I • Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia in Ischemic Cardiomyopathy (VANISH2) • Randomized Comparison of Left Atrial Appendage Closure With Oral Anticoagulation After Catheter Ablation for Atrial Fibrillation (OPTION) • Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN AF) LBS.03: Smart Cardiology: Harnessing AI and Innovation for Better Heart Health 3:15-4:30 p.m. | Main Event I • Evaluation of Randomized Audit and Feedback to Increase Heart Failure Medication Optimization Among Primary Care Pharmacists in the Veterans Affairs Health Care System (PHARM-HF A&F Study) • Novel AI to Assess Intracardiac Filling Pressure: The Noninvasive SEISMocardiogram in Cardiovascular Monitoring for Heart Failure I (SEISMIC-HF I) Study • Artificial Intelligence-Based Automated ECHOcardiographic Measurements and the Workflow of Sonographers (AI-ECHO): Randomized Crossover Trial • PanEcho: Complete AIenabled Echocardiography Interpretation With Multitask Deep Learning Featured Science FS.01: Novel Approaches to Managing Lipid Risk 1:30-2:45 p.m. | S100A • Long-Term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72-Week Open-Label Extension Trial (LIBerate-OLE) • Efficacy and Safety of Lerodalcibep, a ThirdGeneration PCSK9 Inhibitor, in 703 Heterozygous Familial Hypercholesterolemia Subjects in the Open Label Extension Trial (LIBerate-HeFH_OLE) • PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in Adults With Genetically or Clinically Defined Familial Chylomicronemia Syndrome (FCS) at High Risk of Acute Pancreatitis (AP) • Transcriptomic Signatures and Predictors of Evolocumab Added to Maximum Statin Therapy Based on Intra-Coronary Plaque Characteristics: YELLOW III Study FS.02: Health Technology and the Future of Clinical Trials 1:30-2:45 p.m. | S104B • Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials (DELIVER) • Manual vs. AI-Assisted Clinical Trial Screening Using LargeLanguage Models (MAPS-LLM) • Personalized App-Based Coaching Improves Physical Activity in Patients With HFpEF Compared to Standard Care: A Randomized Parallel Group Trial (MyoMobile Study) • Impact of TechnologyEnabled Home-Based Cardiac Rehabilitation on Functional Status and Cardiovascular Health Metrics: The American Heart Association Health Technology Network mTECHRehab Randomized Controlled Trial (mTECH-Rehab) Welcome to Scientific Sessions 2024 in Chicago, where you will find the best in cardiovascular science and medicine. Main Events Generative AI in Cardiovascular Health: A Transformative Force 10-11:15 a.m. | Saturday, Nov. 16 | Main Event I Update on CV Disorders That Disproportionately Affect Women 1:30-2:45 p.m. | Saturday, Nov. 16 | Main Event II Fellowship of the Ring: Atrial Fibrillation and Heart Failure, a Collaborative Journey Through the New Middle Earth 3:15-4:30 p.m. | Saturday, Nov. 16 | Main Event II Don’t miss ... Simulation Zone | Heart Hub Cardiogenic Shock Masterclass: For those interested in taking a deep dive into aspects of diagnosis and management. Sign up for the 2-4 p.m. Masterclass. Each class runs for 60 minutes. Timeslots for Sunday and Monday are also available. Annual Dr. Nanette K. Wenger Research Goes Red® Award for Best Scientific Article on Cardiovascular Disease and Stroke in Women 9:45-11 a.m. | S100A Scan the QR code for the full schedule of Late-Breaking Science and Featured Science sessions. Use #AHA24 to share your highlights and join the conversation online. Scan the QR code to view the Industry Programming Guide. Meet the Trialist MTT.01: nex-Z and BPROAD* 3:15–4 p.m. | Overflow Theater 2, North Building, Level 2
RkJQdWJsaXNoZXIy MjI2NjI=